CV Sciences, Inc.
CVSIdata completeness 100%15 fiscal years on fileCV Sciences, Inc. earns about -103% on invested capital, but has diluted owners by 71% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $20M1 | $16.2M2 | $16M3 | $15.7M4 | $13.8M4 |
| Net income | −$15.6M5 | −$8.21M6 | $3.1M7 | −$2.39M8 | −$958,0008 |
| Operating cash flow | −$7.49M9 | −$1.89M10 | $2.25M11 | −$861,00012 | −$407,00012 |
| Capital expenditure | $35,00013 | $013 | $014 | $18,00015 | $109,00015 |
| Free cash flow (derived) | −$7.52M9 | −$1.89M10 | $2.25M11 | −$879,00012 | −$516,00012 |
| Total debt | $310,00016 | — | — | $677,00017 | $3.3M17 |
| Cash & equivalents | $1.38M18 | $611,00018 | $1.32M19 | $454,00019 | $278,00019 |
| Diluted shares | 107.8M | 138.0M | 154.0M | 175.6M | 184.3M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on $0.08 of net worth that earned you −$0.05 and generated −$0.03 of cash last year, against $0.18 of debt.
It earned an average -103% on invested capital over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is up 71% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has risen 964% over the same window.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2021-12-31 · accession 0001510964-23-000016 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-12-31 · accession 0000950170-24-038736 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2023-12-31 · accession 0000950170-25-046180 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2024-12-31 · accession 0001193125-26-126598 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2021-12-31 · accession 0001510964-23-000016 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0000950170-24-038736 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0000950170-25-046180 (NetIncomeLoss)
- 10-K · period ending 2024-12-31 · accession 0001193125-26-126598 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0001510964-23-000016 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0000950170-24-038736 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0000950170-25-046180 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-12-31 · accession 0001193125-26-126598 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0001510964-23-000016 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-12-31 · accession 0000950170-25-046180 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2024-12-31 · accession 0001193125-26-126598 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2021-12-31 · accession 0001510964-22-000033 (LongTermDebtNoncurrent)
- 10-K · period ending 2024-12-31 · accession 0001193125-26-126598 (LongTermDebtNoncurrent)
- 10-K · period ending 2021-12-31 · accession 0001510964-23-000016 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0001193125-26-126598 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)